Panacea Innovation Ltd - 12 Jan 2026 Form 4 Insider Report for Atara Biotherapeutics, Inc. (ATRA)

Role
10%+ Owner
Signature
Panacea Innovation Limited By: /s/ James Huang, Founding Managing Partner
Issuer symbol
ATRA
Transactions as of
12 Jan 2026
Net transactions value
-$489,019
Form type
4
Filing time
14 Jan 2026, 21:16:25 UTC
Previous filing
01 Dec 2025
SEC
View on sec.gov

Reporting Owners (2)

Name Relationship Address Signature Signature date CIK
Panacea Innovation Ltd 10%+ Owner C/O MAPLES CORPORATE SERVICES LIMITED,, UGLAND HOUSE, GRAND CAYMAN, CAYMAN ISLANDS Panacea Innovation Limited By: /s/ James Huang, Founding Managing Partner 14 Jan 2026 0002010692
Huang James Director, 10%+ Owner C/O MAPLES CORPORATE SERVICES LIMITED,, UGLAND HOUSE, GRAND CAYMAN, CAYMAN ISLANDS /s/ James Huang 14 Jan 2026 0001573160

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ATRA Common Stock Sale $489,019 -80,554 -5.7% $6.07 1,324,446 12 Jan 2026 See Footnotes F1, F2, F3
holding ATRA Common Stock 48,736 12 Jan 2026 See Footnotes F2, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents securities held by Panacea Venture Healthcare Fund II, L.P.
F2 James Huang is the sole owner of Panacea Innovation Limited, which is the sole owner of Panacea Venture Healthcare Fund II GP Company, Ltd. ("Fund II GP") and Panacea Opportunity Fund I GP Company, Ltd. ("Opportunity Fund GP"), which are the general partners of Panacea Venture Healthcare Fund II, L.P. and Panacea Opportunity Fund I, L.P. As a result, each of the Reporting Persons may be deemed to share beneficial ownership of the securities held of record by Panacea Venture Healthcare Fund II, L.P. and Panacea Opportunity Fund I, L.P., but each disclaims such beneficial ownership.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $5.9888 to $6.2838, inclusive. The Reporting Person undertake to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F4 Represents securities held by Panacea Opportunity Fund I, L.P.